Diagnostics News and Research

RSS

Rubicon Genomics reaches agreement with ZyGEM to market its PicoPlex single-cell amplification kits

Rubicon Genomics, Inc., a developer of pre-analytical amplification products that enable more comprehensive genetic analysis of clinical and research samples, announced today that it has reached agreement with ZyGEM to non-exclusively market Rubicon's PicoPlex™ single-cell amplification kits in Australia and New Zealand.

30 Jan 2010

Agent-enhanced CT scan plays a supporting role in diagnosing severe cases of H1N1 flu virus

Published reports on the usefulness of CT scans for complicated H1N1 cases have spurred use of these procedures in U.S. hospitals. According to healthcare market research publisher Kalorama Information, this opens up a pathway of diagnostics for physicians and overall is a positive sign not only for the technology but also for companies making chemical agents for procedures.

29 Jan 2010

Quantrx Biomedical signs agreement to acquire NuRx Pharmaceuticals

QuantRx Biomedical Corporation today announced that it has entered into an agreement to acquire NuRx Pharmaceuticals, Inc. (OTCBB: NUXP). The transaction is structured as a tax-free, all stock acquisition resulting in a combined company with no debt and a simplified ownership and capital structure.

29 Jan 2010

Global market for oncology drugs is forecast to reach $80 billion by 2050

New Medicine's Oncology KnowledgeBASE (nm/OK) residing at http://nmok.net became available on the Internet 10 years ago and, since then, the oncology field has evolved into one of the most challenging, complex and promising drug development sectors, both in terms of its potential contribution to medicine and to its market opportunities.

29 Jan 2010

QIAGEN hosts panel discussion to educate public about the emerging promise of personalized medicine

The treatment of illness has traditionally been based on the law of averages – what works best for the largest number of patients. As a result, billions of dollars are spent every year on treatments that could be ineffective or even harmful for some patients. What if doctors could tell with a simple test which course of treatment would be best for a particular patient?

From QIAGEN Manchester Limited 29 Jan 2010

AMP releases new position statement on the oversight of LDTs

Today, the Association for Molecular Pathology (AMP) released its new position statement on the oversight of laboratory developed tests (LDTs), a recent focus of debate among policy makers, the laboratory community and other stakeholders.

29 Jan 2010

CAMH signs licensing agreement to develop and market genetic test for degenerative muscle disorder

The Centre for Addiction and Mental Health (CAMH) has signed a licensing agreement with a Massachusetts firm to develop and market an innovative genetic test for a recently identified degenerative muscle disorder. The disorder tends to strike adults in their early 30s.

From Thermo Fisher Scientific Inc. 29 Jan 2010

VisEn Medical acquires Bayer Schering Pharma AG's fluorescence agent intellectual property portfolios

VisEn Medical Inc., a leader in fluorescence in vivo imaging from research through medicine, announced today that it has acquired the fluorescence imaging agent intellectual property portfolios and related technology platforms from Bayer Schering Pharma AG, Germany.

29 Jan 2010

Procter & Gamble reports increased net sales for October - December quarter

The Procter & Gamble Company delivered net sales growth of six percent for the October - December quarter to $21.0 billion. Organic sales grew five percent which was at the top of the Company's guidance range.

28 Jan 2010

BD announces first-quarter fiscal 2010 results

BD today reported quarterly revenues of $1.917 billion for the first fiscal quarter ended December 31, 2009, representing an increase of 12 percent from the prior-year period, or 9 percent on a foreign currency-neutral basis.

From BD (Becton, Dickinson and Company) 28 Jan 2010

Life Technologies announces a series of investments and new technologies for genetic sequencing research

Life Technologies Corporation (NASDAQ:LIFE), a provider of innovative life science solutions, today announced a series of investments and new technologies designed to extend the use of sequencing in the research arena and make it more relevant for physicians.

28 Jan 2010

BG Medicine launches new, CE-marked galectin-3 test

BG Medicine, Inc., a privately-held developer of biomarker-based in vitro diagnostics, today announced the commercial launch in the European Union of a new, CE-marked test for the measurement of galectin-3 in human plasma or serum. Galectin-3 was first shown by researchers at the University of Maastricht, The Netherlands, to play an integral role in the development and progression of heart failure.

27 Jan 2010

Abbott declares quarterly dividend of 40 cents per share

Abbott today announced financial results for the fourth quarter ended Dec. 31, 2009.

27 Jan 2010

VentriPoint Diagnostics to present abstract on VMS clinical validation study

VentriPoint Diagnostics Ltd. today announced the abstract of a clinical validation study of the second application of the VentriPoint Medical System (VMS) will be presented at the American College of Cardiology's 59th Annual Scientific Session, March 14 to 16 in Atlanta, Georgia. The study demonstrates the accuracy of the method used by the VentriPoint Medical System (VMS) to generate critical heart measurements in three dimensions from two-dimensional ultrasound images with significantly greater speed and accuracy and at considerably lesser cost than is otherwise possible.

27 Jan 2010

New screening technique identifies early signs of cancer

A new technique to catch cancer early has taken an important step forward thanks to the National Physical Laboratory (NPL). NPL's 'phantoms' will ensure an exciting new screening technique can be relied upon by hospitals to identify early signs of cancer.

27 Jan 2010

Biomoda applauds Senator for introducing legislative bill for lung cancer screening

Cancer diagnostics company Biomoda, Inc. (www.biomoda.com) today applauded Nebraska State Sen. Bob Krist and his co-sponsors for introducing legislation to screen up to 500 Nebraska veterans for early-stage lung cancer.

27 Jan 2010

Quest Diagnostics expands share repurchase program

Quest Diagnostics Incorporated, the world's leading provider of diagnostic testing, information and services, announced that its Board of Directors increased the company's share repurchase authorization by $750 million.

From Quest Diagnostics 27 Jan 2010

Prometheus Laboratories executes commercialization agreement with Novartis

Prometheus Laboratories Inc., a specialty pharmaceutical and diagnostic company, today announced the execution of a commercialization agreement with Novartis under which Prometheus acquired exclusive rights to distribute, promote and sell PROLEUKIN® (aldesleukin) in the United States.

27 Jan 2010

Phadia's ImmunoCAP Rapid System receives FDA marketing clearance

Phadia, the world leader in allergy blood testing diagnostics, today announced that the United States Food and Drug Administration (FDA) has cleared the ImmunoCAP® Rapid Reader II, a part of the ImmunoCAP Rapid System, used to aid in the diagnosis of allergy in the physician’s office.

27 Jan 2010

Abbott submits Premarket Approval application for the ARCHITECT HIV Ag/Ab Combo assay to FDA

An assay to aid in the early detection of HIV infection may soon be available in the United States. Abbott announced today it has submitted a Premarket Approval application for the ARCHITECT HIV Ag/Ab Combo assay to the U.S. Food and Drug Administration (FDA) for expedited review. Upon approval, the assay is expected to be the first test available in the United States to simultaneously detect the combined presence of HIV antigens (proteins produced by the HIV virus) and antibodies (proteins produced by the body to fight HIV antigens), which would allow for the early detection and ongoing monitoring of the virus.

26 Jan 2010

Diagnostics News and Research

Rubicon Genomics reaches agreement with ZyGEM to market its PicoPlex single-cell amplification kits

Agent-enhanced CT scan plays a supporting role in diagnosing severe cases of H1N1 flu virus

Quantrx Biomedical signs agreement to acquire NuRx Pharmaceuticals

Global market for oncology drugs is forecast to reach $80 billion by 2050

QIAGEN hosts panel discussion to educate public about the emerging promise of personalized medicine

AMP releases new position statement on the oversight of LDTs

CAMH signs licensing agreement to develop and market genetic test for degenerative muscle disorder

VisEn Medical acquires Bayer Schering Pharma AG's fluorescence agent intellectual property portfolios

Procter & Gamble reports increased net sales for October - December quarter

BD announces first-quarter fiscal 2010 results

Life Technologies announces a series of investments and new technologies for genetic sequencing research

BG Medicine launches new, CE-marked galectin-3 test

Abbott declares quarterly dividend of 40 cents per share

VentriPoint Diagnostics to present abstract on VMS clinical validation study

New screening technique identifies early signs of cancer

Biomoda applauds Senator for introducing legislative bill for lung cancer screening

Quest Diagnostics expands share repurchase program

Prometheus Laboratories executes commercialization agreement with Novartis

Phadia's ImmunoCAP Rapid System receives FDA marketing clearance

Abbott submits Premarket Approval application for the ARCHITECT HIV Ag/Ab Combo assay to FDA

Sensing a Healthier Future

Achieving and maintaining ISO/IEC 27001 and BS 10012 certifications

Expanding research and clinical options for children with cancer

Latest News